Effect of aflibercept in wet age-related macular degenaration (wAMD) with retinal pigment epithelium detachment (PED)

Effect of aflibercept in wet age-related macular degenaration (wAMD) with retinal pigment epithelium detachment (PED) - Effect of aflibercept in wAMD with PED

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011273

Enrollment

Registered

2013-07-25

Start date

2013-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

exudative age related macular degeneration

Interventions

aflibercept

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Willingness to provide written informed consent 2) wAMD with CNV on FA, ICGA, OCT 3) PED (>1 disc diameter) on OCT 4) Treatment na&iuml;ve 5) BCVA > 0.1 (decimal score)

Exclusion criteria

Exclusion criteria: 1) Drusenoid PED 2) Avascular PED 3) GLD of the total lesion area > 12 4) Presence of RPE tears or macular hole 5) Subretinal hemorrhage, scar or macular fibrosis (>50% lesion area) 5) History of Triamcinolone (< 6 months), dexamethasone (< 30 days), intraocular surgery (< 6 months) 6) Vitrectomy, submacular surgery, etc. 7) Active intraocular inflammation 8) Hypersensitivity or allergy to fluorescein, indocyanine green, etc. 9) Pregnancy, lactating woman

Design outcomes

Primary

Measure	Time frame
1) Ratio of patients with improved/maintained BCVA at month 12 2) Ratio of patients with PED regression	—

Secondary

Measure	Time frame
Change of BCVA, PED, central macular thickness, polyp lesion, etc.	—

Countries

Japan

Contacts

Public ContactYoshimi Nagai

Kansai Medical University Department of Ophthalmology

nagaiy@hirakata.kmu.ac.jp072-804-0101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026